Genzyme Corporation

Glyscend, Inc.

Glycologix, LLC

The Johns Hopkins University

Geltex Pharmaceuticals, Inc.

Entrega Inc.

Thomas Henry Jozefiak

Cecilia M Bastos

Ashish Nimgaonkar

David J Harris

Edward R Lee

Richard A Silva

Yibin Xiang

Cassandra Celatka

Frederic Vinick

Lisa M Cuff

Junkai Liao

John Kane

Mikaela Levine

Steven C Polomoscanik

Stephen Randall Holmes-Farley

W Harry Mandeville, Iii

Pankaj Jay Pasricha

Carlo Giovanni Traverso

Craig S Siegel

Chad Cori Huval

Arthur J Coury

Christopher R Loose

Angeles Dios

Venkata R Garigapati

Colin R Gardner

Keith K Shackett

Danny Concagh

Richard W Heidebrecht, Jr

Kevin Colbert

Andrew T Papoulis

Michael Parlato

David Lucchino

Pratik Patel

Ayush Verma

John Jantz

Cassandra A Celatka

Daniel Bonner

Peter Tran

Yabin Xiang

Andrew Craig Miller

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Substituted phenyl boronic acid containing polymers and methods of use

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Sulfated glycosaminoglycan biomaterials as proteoglycan mimics

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue degenerative conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

Composition and method for treatment of metabolic disorders

A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-&#x3b1;, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I):  Each Ris independently &#x2014;H, lower alkyl, substituted lower alkyl, aryl or substituted aryl. Each Rb is independently &#x2014;H, a lower alkyl group, or a phosphate protecting group.

Phosphate transport inhibitors

Growing community of inventors

Belmont, MA, United States of America

Thomas Henry Jozefiak